中国肿瘤临床 2012, **Vol. 39** Issue (12): 871-873 DOI: doi:10.3969/j.issn.1000-8179.2012.12.015

Gli转录因子与肿瘤

盛晓琳，洪 璇，综述，陈公琰，审校

哈尔滨医科大学附属第三医院内一科 （哈尔滨市150081）

Gli Transcription Factors and Tumor

Xiaolin SHENG, Xuan HONG, Gongyan CHEN

The First Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin 150081, China

摘要

参考文献

相关文章

全文: PDF (493 KB) HTML (1 KB) 输出: BibTeX | EndNote (RIS) 背景资料

摘要 Hedgehog（HH）信号通路参与胚胎发育、成人组织再生及修复，且在肿瘤细胞生长及转移过程中发挥重要作用。已有大量研究证实该信号通路的异常激活与多种肿瘤的发生发展密切相关。Gli是HH通路直接调控靶基因的转录因子，是该通路不同水平激活的最后共同通道，在致瘤过程中起着重要作用。Gli受多通路多因素调节，故抑制Gli靶向性治疗具有非常广阔的前景。本文对Hedgehog-Gli信号通路在恶性肿瘤发生发展中的作用、Gli转录活性的调控及致瘤作用、Gli转录因子的靶向治疗价值等方面的研究进展进行综述。

关键词： Hedgehog Gli 转录因子 肿瘤

Abstract: The hedgehog (HH) signaling pathway plays an important role in the growth and metastasis of tumor cells, in addition to its role in the development of the embryo and the regeneration and repair of tissues in adults. Aberrant activation of this pathway has been found to be involved in the invasion and progression of several malignant human tumors. The Gli transcription factors that directly regulate the transcription of targeted genes act at the end of the Hh signaling cascade, and play an important role in carcinogenesis. Gli has also been found to interact with other signaling pathways commonly activated in human cancers; as such, the targeted inhibition of Gli-mediated transcription is likely valuable during the development of novel agents. The focus of this review is to summarize a number of the known mechanisms of HH - Gli signaling in tumor development. The review also aims to discuss its emerging role in cancer, the transcriptional activity and the carcinogenesis of Gli, major advances in the role of Gli in the HH signaling pathway, and its prospects in clinical applications.

Key words: Hedgehog signaling pathway Gli Transcription factors Neoplasm

收稿日期: 2011-12-28; 出版日期: 2012-06-30

通讯作者: 陈公琰 **E-mail:** chengongyan@medmail.com.cn

引用本文:

. Gli转录因子与肿瘤[J]. 中国肿瘤临床, 2012, 39(12): 871-873.

. Gli Transcription Factors and Tumor[J]. Chinese Journal of Clinical Oncology, 2012, 39(12): 871-873.

链接本文:

http://118.145.16.228:8081/Jweb_zgzllc/CN/doi:10.3969/j.issn.1000-8179.2012.12.015 或 http://118.145.16.228:8081/Jweb_zgzllc/CN/Y2012/V39/I12/871

服务

把本文推荐给朋友

加入我的书架

加入引用管理器

E-mail Alert

RSS

作者相关文章

[1] 李　慧. 肿瘤干细胞对肿瘤血管生成的作用及调控机制的最新研究进展[J]. 中国肿瘤临床, 2012, 39(9): 493-496.

[2] 周　莉,徐运孝. 调节性**T**细胞在慢性粒细胞白血病中的表达及临床意义[J]. 中国肿瘤临床, 2012, 39(9): 502-505.

[3] 齐　瑶,李润美,于津浦,李　慧,尤　健,于文文,辛　宁. **Vav1**与浸润**T**细胞活性 肿瘤局部**IDO**表达相关性的研究[J]. 中国肿瘤临床, 2012, 39(9): 524-528.

[4] 何宋兵,综述,朱新国,审校. **Th17**细胞与肿瘤免疫的研究进展[J]. 中国肿瘤临床, 2012, 39(9): 529-531.

[5] 程　艳,姚　丽,崔金全. 卵巢癌中**PGRMC1**基因表达与微血管密度的关系[J]. 中国肿瘤临床, 2012, 39(9): 583-586.

[6] 刘晓东,汪　旭,贾勇圣,王　蕊,佟仲生. 三阴性对小肿块乳腺癌患者预后的影响[J]. 中国肿瘤临床, 2012, 39(9): 578-582.

[7] 尹婧婧,周礼鲲,李鸿立,巴　一. 循环肿瘤细胞与乳腺癌患者预后相关性的**Meta**分析[J]. 中国肿瘤临床, 2012, 39(9): 602-606.

[8] 蒋　萱,王　东,杨雪琴,单锦露,王　阁,杨镇洲,李增鹏,杨宇馨. 多肿瘤标志物蛋白芯片检测中**CA125**对恶性肿瘤的诊断价值[J]. 中国肿瘤临床, 2012, 39(9): 6
610.

[9] 宋　东,杨晓玲,冯慧晶,韩亚萍,刘静毅,张俊萍. **DC-CIK**联合化疗治疗消化道肿瘤临床疗效分析[J]. 中国肿瘤临床, 2012, 39(9): 497-501.

[10] 潘利华，陈雪松，综述，蔡　莉，审校. 乳腺癌预后评估系统的研究进展[J]. 中国肿瘤临床, 2012, 39(8): 472-475.

[11] 朱　雯，综述，王朝霞，审校. 长链非编码**RNA**与肿瘤研究进展[J]. 中国肿瘤临床, 2012, 39(8): 476-480.

[12] 冯亚光，魏正强，曾绍兵，潘　屹. **Gli1**和**Foxm1**在胃癌中的表达及其临床意义[J]. 中国肿瘤临床, 2012, 39(7): 377-381.

[13] 赵立武，申　彦，师宜茎，刘　艳，刘易欣. **P16 P53 CyclinD1**在卵巢浆液性癌中的表达及意义[J]. 中国肿瘤临床, 2012, 39(7): 388-391.